JP2016527920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527920A5 JP2016527920A5 JP2016536482A JP2016536482A JP2016527920A5 JP 2016527920 A5 JP2016527920 A5 JP 2016527920A5 JP 2016536482 A JP2016536482 A JP 2016536482A JP 2016536482 A JP2016536482 A JP 2016536482A JP 2016527920 A5 JP2016527920 A5 JP 2016527920A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- oncolytic vaccinia
- deletion
- virus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700618 Vaccinia virus Species 0.000 claims description 44
- 230000000174 oncolytic effect Effects 0.000 claims description 43
- 230000004048 modification Effects 0.000 claims description 40
- 238000012986 modification Methods 0.000 claims description 40
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 230000013595 glycosylation Effects 0.000 claims description 26
- 238000006206 glycosylation reaction Methods 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 15
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 claims description 12
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 claims description 12
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims description 10
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims description 10
- 230000005867 T cell response Effects 0.000 claims description 10
- 206010062016 Immunosuppression Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 6
- 229960002986 dinoprostone Drugs 0.000 claims description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 6
- 230000007482 viral spreading Effects 0.000 claims description 6
- 101150074766 C12L gene Proteins 0.000 claims description 4
- 102220508636 Liprin-beta-1_C12L_mutation Human genes 0.000 claims description 4
- 101150009018 SPI-1 gene Proteins 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 101150108168 A33R gene Proteins 0.000 claims description 2
- 101150076005 A36R gene Proteins 0.000 claims description 2
- 101150023320 B16R gene Proteins 0.000 claims description 2
- 102220477045 Dynein axonemal assembly factor 10_A56R_mutation Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101150039660 HA gene Proteins 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 claims description 2
- 101100000236 Vaccinia virus (strain Western Reserve) VACWR159 gene Proteins 0.000 claims description 2
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 2
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 2
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004075 alteration Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| US61/868,978 | 2013-08-22 | ||
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133264A Division JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527920A JP2016527920A (ja) | 2016-09-15 |
| JP2016527920A5 true JP2016527920A5 (https=) | 2017-09-28 |
| JP6912199B2 JP6912199B2 (ja) | 2021-08-04 |
Family
ID=52484194
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536482A Active JP6912199B2 (ja) | 2013-08-22 | 2014-08-22 | 免疫腫瘍溶解療法 |
| JP2019133264A Active JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
| JP2022015459A Active JP7333431B2 (ja) | 2013-08-22 | 2022-02-03 | 免疫腫瘍溶解療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133264A Active JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
| JP2022015459A Active JP7333431B2 (ja) | 2013-08-22 | 2022-02-03 | 免疫腫瘍溶解療法 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (https=) |
| EP (3) | EP4324918A3 (https=) |
| JP (3) | JP6912199B2 (https=) |
| KR (1) | KR102389240B1 (https=) |
| CN (1) | CN105658795B (https=) |
| AU (1) | AU2014308648B2 (https=) |
| CA (3) | CA3213683A1 (https=) |
| CY (1) | CY1126587T1 (https=) |
| DK (2) | DK3778897T3 (https=) |
| EA (1) | EA037582B1 (https=) |
| ES (2) | ES2847305T3 (https=) |
| FI (1) | FI3778897T3 (https=) |
| HR (1) | HRP20240078T1 (https=) |
| HU (1) | HUE066593T2 (https=) |
| IL (1) | IL243996A0 (https=) |
| LT (1) | LT3778897T (https=) |
| MD (2) | MD4624C1 (https=) |
| MX (1) | MX2016002257A (https=) |
| NZ (1) | NZ716825A (https=) |
| PE (1) | PE20160673A1 (https=) |
| PH (1) | PH12016500329A1 (https=) |
| PL (1) | PL3778897T3 (https=) |
| PT (1) | PT3778897T (https=) |
| RS (1) | RS65104B1 (https=) |
| SG (1) | SG11201600960PA (https=) |
| SI (1) | SI3778897T1 (https=) |
| SM (1) | SMT202400047T1 (https=) |
| WO (1) | WO2015027163A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| WO2017014296A1 (ja) * | 2015-07-22 | 2017-01-26 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| WO2017043815A1 (en) * | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
| WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| CN109152736A (zh) * | 2016-03-25 | 2019-01-04 | 联邦高等教育系统匹兹堡大学 | 合成包封病毒 |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| CA3070146A1 (en) * | 2016-07-19 | 2018-01-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting stat3 |
| AU2017332367B2 (en) * | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| EP3593136A1 (en) * | 2017-03-06 | 2020-01-15 | Talaris Therapeutics, Inc. | Methods and compositions for determining the potency of a therapeutic cellular composition |
| EP4286009A3 (en) * | 2017-04-21 | 2024-04-03 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| CA3082961A1 (en) | 2017-12-01 | 2019-06-06 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| EP3898997A4 (en) * | 2018-12-21 | 2022-11-16 | Ottawa Hospital Research Institute | MODIFIED ORTHOPOXVIRUS VECTORS |
| CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| WO2020165730A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3150829A1 (en) * | 2019-08-26 | 2021-03-04 | Bionoxx Inc. | Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| WO2021140435A1 (en) * | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
| KR20220152250A (ko) * | 2020-03-06 | 2022-11-15 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스 |
| US20230355804A1 (en) * | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| AU2022303363A1 (en) * | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| IL318055A (en) * | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9305855A (es) | 1992-09-24 | 1995-01-31 | Tadatsugu Taniguchi | Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. |
| WO2000073479A1 (en) | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2002064159A1 (fr) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs affectant les organes hematopoietiques |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| JPWO2007023725A1 (ja) * | 2005-08-25 | 2009-02-26 | 公立大学法人横浜市立大学 | 遺伝子ワクチン |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| ES2848650T3 (es) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| RS65104B1 (sr) | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
-
2014
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US12514888B2/en active Active
-
2024
- 2024-01-30 CY CY20241100073T patent/CY1126587T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527920A5 (https=) | ||
| HRP20240078T1 (hr) | Imuno-onkolitičke terapije | |
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| Zeh et al. | Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers | |
| Everts et al. | Replication-selective oncolytic viruses in the treatment of cancer | |
| CN101868546B (zh) | 痘病毒溶瘤载体 | |
| CN111344398A (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| Wang et al. | Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity | |
| Keller et al. | Oncolytic viruses—immunotherapeutics on the rise | |
| JP2015506179A5 (https=) | ||
| JP2021500932A5 (https=) | ||
| EA201690545A1 (ru) | Онколитические аденовирусы, несущие гетерологичные гены | |
| NZ628385A (en) | Batches of recombinant adenovirus with altered terminal ends | |
| JP2014207903A5 (https=) | ||
| RU2017134519A (ru) | Терапевтические композиции и способы применения для лечения рака | |
| JP2014509197A (ja) | 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用 | |
| Yang et al. | Progress in gene therapy using oncolytic vaccinia virus as vectors | |
| Futami et al. | Efficacy and safety of doubly-regulated vaccinia virus in a mouse xenograft model of multiple myeloma | |
| Rivera-Orellana et al. | Oncolytic virotherapy and tumor microenvironment modulation | |
| JP2020014467A (ja) | 非複製型ウイルス由来粒子及びその使用 | |
| WO2009101149A3 (en) | Anti-tumour effective paramyxovirus | |
| Schafer et al. | NK cell exhaustion: bad news for chronic disease? | |
| JP2019517262A5 (https=) | ||
| Nistal-Villan et al. | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model |